Table 3 |
|||
|
Adverse events [n (%)] occurring in ≥ 10% of subjects in any treatment group |
|||
|
Event |
Treatment Regimen A (fasting; n = 28) |
Treatment Regimen B (fed; n = 29) |
Treatment Regimen C (fasting with naltrexone block; n = 27) |
|
|
|||
|
Nausea |
6 (21.4) |
9 (31.0) |
7 (25.9) |
|
Asthenia |
6 (21.4) |
8 (27.6) |
7 (25.9) |
|
Dizziness |
8 (28.6) |
5 (17.2) |
3 (11.1) |
|
Pruritus |
2 (7.1) |
4 (13.8) |
9 (33.3) |
|
Headache |
6 (21.4) |
3 (10.3) |
4 (14.8) |
|
Vomiting |
2 (7.1) |
3 (10.3) |
5 (18.5) |
|
|
|||
|
Sathyan et al. BMC Clinical Pharmacology 2007 7:2 doi:10.1186/1472-6904-7-2 |
|||
